Regulatory issues on both sides of the Atlantic held back growth at Sanofi’s Consumer Healthcare business in the third quarter as sales edged up by 0.4% at constant exchange rates to €1.14bn ($1.27bn).
US turnover fell by 4.4% to €252m in the three months as Sanofi began to feel the effects of a...





